var data={"title":"Rubidium rb-82: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rubidium rb-82: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/713591?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613466\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Radiation exposure:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Unintended radiation exposure occurs when the levels of strontium-82 (Sr-82) or strontium-85 (Sr-85) in rubidium Rb 82 chloride exceed specified limits.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Record each generator eluate volume, including waste and test volumes, and keep a record of the cumulative eluate volume.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Determine Rb-82, Sr-82, Sr-85 in the generator eluate once a day, prior to any drug administrations, and at additional daily tests after detection of an alert limit. Alert limits are 14 L for the generator's cumulative eluate volume; or an eluate Sr-82 level of 0.002 mcCi per mCi Rb-82; or an eluate Sr-85 level of 0.02 Sr-85 mcCi per mCi Rb-82. Perform the additional daily tests at time points determined by the days elution volume; tests are performed every 750 mL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Stop use of a generator at an expiration limit of 17 L for the generator's cumulative eluate volume; 42 days after generator calibration date; an eluate Sr-82 level of 0.01 mcCi per mCi Rb-82; or an eluate Sr-85 level of 0.1 mcCi per mCi Rb-82.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613467\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CardioGen-82</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613471\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613548\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Individualize the dose by considering factors such as body size and the imaging equipment and technique. Use the lowest dose necessary to obtain adequate cardiac visualization consistent with the dosing goal of as low as reasonably achievable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Myocardial perfusion imaging: </b>IV: Rest or stress imaging: 40 mCi (1,480 MBq) as a single dose; dosage range: 30 to 60 mCi (1,110 to 2,220 MBq); maximum single dose: 60 mCi (2,220 MBq).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46304177\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Lengthen the delay between infusion and image acquisition; use with caution. Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613499\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; renal impairment is not expected to alter clearance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613500\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; hepatic impairment is not expected to alter clearance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613305\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Generator Column, for elution in producing Rubidium-82 chloride for injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CardioGen-82: Strontium Sr-82 90-150 mCi per generator system</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613470\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613549\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV administration; administer as 2 separate single doses to complete rest and stress myocardial perfusion imaging. Administer at 50 mL/minute through a catheter inserted into a large peripheral vein; maximum total infusion volume of 100 mL. Radiopharmaceutical; use appropriate precautions for handling and disposal. Ensure adequate hydration before and after administration. To minimize bladder exposure, patients should void frequently for one hour after PET scan completed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Rest imaging:</b> Administer as a single dose; start imaging 60 to 90 seconds after completion of infusion and acquire images for 5 minutes; if a longer circulation time is anticipated (eg, patients with severe left ventricular dysfunction), start imaging 120 seconds after the rest dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress imaging:</b> Begin study 10 minutes after completion of rest dose infusion; administer pharmacologic stress agent; after 3 minutes infuse single dose of rubidium-82 chloride; start imaging 60 to 90 seconds after completion of infusion and acquire images for 5 minutes; if a longer circulation time is anticipated (eg, patients with severe left ventricular dysfunction), start imaging 120 seconds after stress dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613474\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Myocardial perfusion imaging:</b> Positron emission tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23621169\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613487\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613488\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Arrhythmias, bronchoconstriction, cerebrovascular events, hypotension, and myocardial infarction (MI) have occurred due to pharmacologic agents used in conjunction with stress imaging. Appropriate measures for resuscitation should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Radiation-emitting products may increase the risk for cancer; use the smallest dose necessary and ensure safe handling to protect patients and healthcare workers.</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use with caution in patients with heart failure; may be at increased risk of volume overload.</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be at increased risk of volume overload. Delay between infusion and imaging should be lengthened.</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>\n        <i>Special handling: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>\n    <p style=\"text-indent:0em;margin-left:0em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Test may be done while patients are at rest or under pharmacologic stress conditions. Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for at least 1 hour following administration to decrease radiation exposure to the bladder. Use only with an infusion system specifically designed for use with the generator and capable of accurate measurement and delivery of doses of rubidium-82 chloride injection. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation exposure: <b>[U.S. Boxed Warning]: Unintended exposure to strontium radiation has occurred when the Sr-82 and Sr-85 levels in rubidium 82 chloride injections have exceeded specified generator eluate limits. Strict adherence to a daily eluate testing protocol must be followed.</b> Unintended exposure to strontium radiation does contribute to the patient&rsquo;s overall long-term cumulative radiation dose which is associated with an increased risk of cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23694765\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23694762\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=93591&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613475\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613476\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproductive studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613486\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rubidium-82 is excreted in breast milk. Rubidium-82 has a short half-life and, therefore, it is unlikely that it is excreted in human milk during lactation. The manufacturer recommends to use caution and that formula feedings be substituted until at least 1 hour after the last infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46304178\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fluid overload (especially in elderly and heart failure patients) during and for several hours following infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613492\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which decays by positron and gamma emission to a photon that can be detected by imaging. It is the same as potassium ion in its behavior and is rapidly extracted by the myocardium proportional to blood flow.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613494\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of Action: Myocardial activity: Within 1 minute; if areas of infarction or ischemia are present that may be visualized within 2-7 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Decays rapidly to trace amounts of stable Kr 82 gas which is expired by the lungs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Physical half-life: 75 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (a portion may be excreted prior to radioactive decay)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cardiogen-82 (rubidium rb 82 generator) [prescribing information]. Monroe Twp, NJ: Bracco Diagnostics Inc; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC). Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials. 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 93591 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F23613466\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23613467\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F23613471\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F23613548\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46304177\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F23613499\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F23613500\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F23613305\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F23613470\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23613549\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F23613474\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F23621169\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F23613487\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F23613488\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23694765\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23694762\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F23613475\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F23613476\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F23613486\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46304178\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23613492\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F23613494\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/93591|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}